Long-term outcome of a cohort of Italian patients affected with alpha-Mannosidosis.
Journal
Clinical dysmorphology
ISSN: 1473-5717
Titre abrégé: Clin Dysmorphol
Pays: England
ID NLM: 9207893
Informations de publication
Date de publication:
01 Jan 2024
01 Jan 2024
Historique:
pubmed:
4
10
2023
medline:
4
10
2023
entrez:
4
10
2023
Statut:
ppublish
Résumé
Alpha-mannosidosis (MIM #248500) is an ultra-rare autosomal recessive lysosomal storage disease with multi-system involvement and a wide phenotypic spectrum. Information on long-term outcomes remains poor. We present the long-term outcomes (median, 19 years) of nine patients with alpha-mannosidosis, three females and six males, followed at a single center. The findings of the nine patients were collected from medical records and reported as mean ± SD or median, and range. The age of onset of the first symptoms ranged from 0-1 to 10 years. The diagnostic delay ranged from 2 to 22 years (median= 11 years). Coarse face, hearing, heart valves, joints, gait, language, dysarthria, psychiatric symptoms, I.Q., MRI, walking disabilities, orthopedic disturbances and surgeries showed a slow worsening over the decades. Our patients showed a slowly worsening progressive outcome over the decades. Psychiatric symptoms were present in 100% of our population and improved with the appropriate pharmacological intervention. This aspect requires attention when following up on these patients. Our description of the long-term evolution of alpha-mannosidosis patients may provide basic knowledge for understanding the effects of specific treatments.
Identifiants
pubmed: 37791705
doi: 10.1097/MCD.0000000000000474
pii: 00019605-990000000-00049
pmc: PMC10702697
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-8Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Adam J, Malone R, Lloyd S, Lee J, Hendriksz CJ, Ramaswami U (2019). Disease progression of alpha-mannosidosis and impact on patients and carers - a UK natural history survey. Mol Genet Metab Rep 20:100480.
Beck M, Olsen KJ, Wraith JE, Zeman J, Michalski JC, Saftig P, et al. (2013). Natural history of alpha mannosidosis a longitudinal study. Orphanet J Rare Dis 8:88.
Chester MA, Lundblad A, Öckerman PA, Autio S (1982). Mannosidosis. In: Durand P, O’Brien JF (eds) Genetic errors of glyco-protein metabolism. Edi-Ermes, Milan, chapt. 4, pp 89–120.
Desnick R, Sharp HL, Grabowski GA, Brunning RD, Quie PG, Sung JH, et al. (1976). Mannosidosis: clinical, morphologic, immunologic, and biochemical studies. Pediat Res 10:985–996.
Guffon N, Tylki-Szymanska A, Borgwardt L, Lund AM, Gil-Campos M, Parini R, et al. (2019). Recognition of alpha-mannosidosis in paediatric and adult patients: Presentation of a diagnostic algorithm from an international working group. Mol Genet Metab 126:470–474.
Harmatz P, Cattaneo F, Ardigò D, Geraci S, Hennermann JB, Guffon N, et al. (2018). Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase): novel global treatment response model and outcomes in patients with alpha-mannosidosis. Mol Genet Metab 124:152–160.
Hennermann J, Raebel EM, Donà F, Jacquemont M-L, Cefalo G, Ballabeni A, Malm D (2022). Mortality in patients with alfa-mannosidosis: a review of patients’ data and the literature. Orphanet J Rare Dis 17:287.
Lipinski P, Rozdzynska-´Swiątkowska A, Iwanicka-Pronicka K, Perkowska B, Pokora P, Tylki-Szymanska A (2021). Long-term outcome of patients with alpha-mannosidosis – A single center study. Mol Genet Metab Rep 30:100826.
Majovska J, Nestrasil I, Paulson A, Nascene D, Jurickova K, Hlavata A, et al. (2021). White matter alteration and cerebellar atrophy are hallmarks of brain MRI in alpha-mannosidosis. Mol Genet Metab 132:189–197.
Malm D, Nilssen O (2008). Alpha–mannosidosis. Orphanet J Rare Dis 3:21.
Malm D, Halvorsen DS, Tranebjaerg L, Sjursen H (2000). Immunodeficiency in alpha-mannosidosis: a matched case-control study on immunoglobulins, complement factors, receptor density, phagocytosis and intracellular killing in leucocytes. Eur J Pediatr 159:699–703.
Malm D, Pantel J, Linaker OM (2005). Psychiatric symptoms in alpha-mannosidosis. J Intellect Disabil Res 49:865–871.
Malm D, Riise Stensland HMF, Edvardsen O, Nilssen O (2014). The natural course and complications of alpha-mannosidosis - a retrospective and descriptive study. J Inherit Metab Dis 37:79–82.
Mynarek M, Tolar J, Albert MH, Escolar ML, Boelens JJ, Cowan MJ, et al. (2012). Allogeneic hematopoietic SCT for alpha-mannosidosis: an analysis of 17 patients. Bone Marrow Transplant 47:352–359.
Öckerman PA (1967). A generalized storage disorder resembling Hurler’s syndrome. Lancet 290:239–241.
Sbaragli M, Bibi L, Pittis MG, Balducci C, Heikinheimo P, Ricci R, et al. (2005). Identification and characterization of five novel MAN2B1 mutations in Italian patients with alpha-mannosidosis. Hum Mutat 25:320.
Zielonka M, Garbade SF, Kölker S, Hoffmann GF, Ries M (2019). Ultra-orphan lysosomal storage diseases: a cross-sectional quantitative analysis of the natural history of alpha-mannosidosis. J Inherit Metab Dis 42:975–983.